Table 5.10.
Therapeutic vaccines in development
| Drug | Platform | Route | Company | Clinical trial phase | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|
| NASVAC (ABX203) | HBs and HBc antigen mixed with carboxyl vinyl polymer [84] | Nasal | CIGB, Cuba | 3 | NCT01374308/NCT02249988 |
| HepTcell (FP-02.2) | Synthetic HBV-derived peptides formulated with IC31®, a TLR9based adjuvant [85] | IM [86] | Altimmune, USA | 2 | NCT02496897 |
| AIC 649 | Parapoxvirus (iPPVO) [87] | IV | AiCuris, Germany | 1 | |
| JNJ 64300535 (HB-110) | Plasmids encoding HBsAg, HBcAg, and IL12 [88] | IM Electroporation | Janssen, Ireland/Ichor Medical Genexine, USA | 1 | NCT03463369 |
| TG1050 | Ad5 which encodes truncated HBV core, POL, and two small domains from the ENV [89] | SC | Transgene, France | 1 | NCT04168333/NCT02909023/NCT04168333 |
| MVA-VLP-HBV | Modified vaccinia Ankara-virus-like particle-hepatitis B virus [90] | GeoVax, USA | Preclinical | n/a | |
| Chimigen HBV | Recombinant chimeric fusion protein comprising hepatitis B virus (HBV) S1 and S2 surface antigen fragments, core antigen, and a murine monoclonal antibody heavy chain fragment (Fc) [91] | Akshaya, Canada | Preclinical | n/a | |
| TherVacB | HBsAg, HBcAg, and a boost using a modified vaccinia virus Ankara (MVA) vector [92] | Helmholtz Zentrum Muenchen, Germany | Preclinical | n/a | |
| 3xT2A and Mix2A | VLVs expressing polymerase (Pol), core (HBcAg), and MHBs [93] | CaroGen, USA | Preclinical | n/a | |
| HBV | TheraT® and VaxWave® investigational arenavirus-based immunization technologies [94] | HOOKIPA Pharma, Austria, with Gilead | Preclinical | n/a | |
| VBI-2601 (BRII-179) | Recombinant, protein-based immunotherapeutic [95] | VBI Vaccines, USA | 1b/2a |
ID intradermal, SC subcutaneous, Ad adenovirus, POL polymerase, ENV envelope, VLV virus-like vesicles, N/A not applicable